AstraZeneca launches FORXIGA for Type 2 diabetes in India
Source: IRIS | 11 Jun, 2015, 11.00AM
|
|
|
|
|
| Rating: NAN / 5 stars. |
 Comments | Post Comment |
|
 AstraZeneca Pharma India announced the launch of FORXIGA® (dapaglifozin), a breakthrough treatment for Type 2 diabetes mellitus.
 FORXIGA® belongs to a new class of Type 2 diabetes mellitus medication-a highly selective inhibitor of sodium-glucose cotransporter 2 (SGLT2). It has an unique insulin independent mode of action that helps remove excess glucose fromt he body via urine which is associated with reductions in glycated haemoglobin (HbA1c), weight and systolic blood pressure. Globally, FORXIGA® is the first medicine in the new SGLT2 inhibitor class to gain regulatory approval for the treatment of Type 2 diabetes mellitus.
Shares of the company gained Rs 88.55, or 9.26%, to trade at Rs 1,045. The total volume of shares traded was 37,301 at the BSE (9.57 a.m., Thursday).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
